Company / Operating Cash Flow
Anika Therapeutics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$11.2M
FY2025
5-year range
-$1.8M / $37.0M
FY2021-FY2025
Trend
+107.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 10 years, ranging from -$2M in FY2023 to $41M in FY2019.
Based on SEC 10-K filings.
$11M in FY2025 with a 5-year CAGR of -20.4%.
Improved from -$2M to $11M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -5.0%
- 5-Year CAGR
- -20.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -20.4%, indicating a declining trend.
- In FY2025, operating cash flow increased 107.1% year-over-year.
- Peak operating cash flow was recorded in FY2019.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.2M | +107.1% |
| FY2024 | $5.4M | +402.2% |
| FY2023 | -$1.8M | -113.7% |
| FY2022 | $13.1M | -64.7% |
| FY2021 | $37.0M | +6.0% |
| FY2020 | $34.9M | -14.4% |
| FY2019 | $40.8M | +66.9% |
| FY2018 | $24.4M | -38.7% |
| FY2017 | $39.9M | -0.2% |
| FY2016 | $40.0M | +58.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026